MoonLake Immunotherapeutics (MLTX) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 4, 2026, with shareholders voting on director election, auditor ratification, executive compensation, and an amended equity incentive plan.

• Only shareholders of record as of April 9, 2026, are eligible to vote, with each Class A Ordinary Share entitled to one vote per proposal.

• Voting can be done online, by phone, mail, or in person, and the Board recommends voting in favor of all proposals.

• Forward-looking statements highlight risks and uncertainties, especially regarding clinical development and regulatory submissions.

Voting matters and shareholder proposals

• Proposals include electing a Class I director (Spike Loy), ratifying Baker Tilly US, LLP as auditor, approving executive compensation (say-on-pay), and amending the 2022 Equity Incentive Plan.

• Shareholders may also transact other business as properly brought before the meeting.

• Shareholder proposals for the 2027 meeting must be submitted by December 22, 2026, to be included in the proxy statement.

Board of directors and corporate governance

• The Board consists of five directors divided into three classes with staggered three-year terms.

• Governance structure includes a classified board, supermajority voting for key changes, and plurality voting for directors.

• The Board annually evaluates governance practices and values shareholder input.

• Committees include Audit, Compensation, and Nominating, each with defined responsibilities and independent members.

• The Lead Independent Director role is currently held by Spike Loy, providing independent oversight.